Comparison of human chorionic gonadotropin (Pregnyl 10 000 IU i.m.) versus GnRH agonist (triptorelin 0,2 mg s.c.) for final oocytes maturation in the same egg donors – clinical and embryological characteristics

Czech version

Authors: R. Středa ^1,2,3,4; T. Mardešič ^1,2; V. Sobotka ^1,2; D. Koryntová ²; L. Hybnerová ²; M. Jindra ²; V. Paseková ¹; J. Slámová ¹; M. Števíková ¹; J. Vobořil ¹; L. Jelínková ¹; Š. Vilímová ¹; J. Ichová ¹; J. Mádrová ¹; H. Teršová ¹; M. Mašata ¹; J. Sobotková ^3,4
Authors‘ workplace: Sanatorium Pronatal, Praha, vedoucí lékař doc. MUDr. T. Mardešič, CSc. ¹; Pronatal Plus s. r. o., Praha, vedoucí lékařka MUDr. D. Koryntová, CSc. ²; Porodnicko-gynekologická klinika, Pardubická krajská nemocnice a. s., přednosta doc. MUDr. M. Košťál, CSc. ³; Fakulta zdravotnických studií, Univerzita Pardubice ⁴
Published in: Ceska Gynekol 2011; 76(2): 113-118

Overview

Objective:
To compare clinical and embryological characteristics in donor cycles triggered for final oocytes maturation with Pregnyl 10 000 IU i.m. versus triptorelin 0.2 mg s.c. in the same patients in two sequential stimulation cycles. The aim of the study is to decrease the risk of the development of ovarian hyperstimulation syndrome (OHSS) at high response donors by the replacement of Pregnyl 10 000 IU i.m. vs. triptorelin 0.2 mg s.c. The administration of a single dose of gonadotropin-releasing hormone agonist (triptorelin 0.2 mg s.c.) induces release of LH from the pituitary gland similarly to a spontaneous LH surge.

Subject:
Prospective cross-over trial.

Setting:
Sanatorium Pronatal, Praha.

Subject and method:
From August 2009 to July 2010 we analysed 24 stimulation cycles in 12 egg donors treated with GnRH antagonist protocol with recombinant FSH (follitropin beta). We identified patients with more than 15 follicles during examination by transvaginal ultrasound. When at least 3 leading follicles reached 17 mm in diameter we administrated Pregnyl 10 000 IU i.m. for final oocytes maturation and triptorelin 0.2 mg s.c in the subsequent treatment cycle.

Results:
The primary outcome measure was number of oocytes, proportion mature oocytes and fertilized oocytes. The secondary outcome were duration of FSH stimulation, total dose of gonadotropins and mean daily dose of gonadotropins. Data was analysed by paired t-test. We retrieved 17,2 ± 8,6 vs. 15,8 ± 5,3 (ns) oocytes, 12,6 ± 7,3 vs. 13,0 ± 5,4 (ns) metaphase II oocytes, proportion of metaphase II oocytes (%) was 73 vs. 83 (ns), number of fertilized oocytes 11,5 ± 6,7 vs. 11,7 ± 4,5 (ns), fertilization rate (%) 91 vs. 90 (ns) in Pregnyl’s vs. triptorelin’s group, resp. Duration of FSH stimulation (days) 12,2 ± 0,8 vs. 12,4 ± 0,7 (ns), total dose of gonadotropins (IU) 1744 ± 277 vs. 1740 ± 276 (ns), mean daily dose of gonadotropins (IU) 238 ± 43 vs. 221 ± 36 (ns), were not statistically different in both groups.

Conclusions:
Number of mature oocytes and subsequent embryonic cleavage is comparable to standard hCG treatment. There are no differences in clinical and embryological characteristics in both groups. Only one patient with administration of Pregnyl 10 000 IU i.m. was treated for OHSS grade II by vaginal paracentesis. Administration of triptorelin 0,2 mg s.c. is a safe and effective approach to achieve mature oocytes in egg donation programme, where we do not take care of implantation, which has got some limitations based on several studies.

Key words:
egg donation, in vitro fertilization, ICSI, hCG, Pregnyl, GnRH agonist, triptorelin, oocyte maturation.

Sources

1. Acevedo, B., Gomez-Palomares, JL., Ricciarelli, E., Hernandez, ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril, 2006, 86, p. 1682-1687.

2. Beckers, NG., Macklon, NS., Eijkemans, MJ., et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab, 2003, 88, p. 4186-4192.

3. Bodri, D., Guillen, JJ., Galindo, A., et al. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril, 2009, 91, p. 365-371.

4. Bodri, D., Guillen, JJ., Trullenque, M., et al. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril, 2010, 93, p. 2418-2420.

5. Brinsden, PR. A textbook of in vitro fertilization and assisted reproduction. New York: Parthenon Publishing, 1999, p. 257-265.

6. Engmann, L., DiLuigi, A., Schmidt, D., et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril, 2008, 89, p. 84-91.

7. Fauser, BC., de Jong, D., Olivennes, F., et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab, 2002, 87, p. 709-715.

8. Galindo, A., Bodri, D., Guillen, JJ., et al. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol, 2009, 25, p. 60-66.

9. Gardner, DK., Weissman, A., Howles, CM., Shoham, Z. Textbook of assisted reproductive techniques, 1st edition, London: Martin Dunitz, 2001, p. 484-491, 645-654.

10. Griesinger, G., Felberbaum, R., Diedrich, K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet, 2005, 273, p. 71-78.

11. Griesinger, G., Diedrich, K., Devroey, P., Kolibianakis, EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update, 2006, 12, p. 159-168.

12. Itskovitz-Eldor, J., Kol, S., Mannaerts, B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod, 2000, 15, p. 1965‑1968.

13. Kol, S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril, 2004, 81, p. 1-5.

14. Kolibianakis, EM., Schultze-Mosgau, A., Schroer, A., et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod, 2005, 20, p. 2887-2892.

15. Koryntova, D., Jelinkova, L., Rezabek, K., Zivny, J. Asistovaná reprodukce - současný stav a perspektivy. Čes Gynekol, 1999, 64, s. 383-388.

16. Mardesic, T. Indikace a výsledky léčby sterility metodami asistované reprodukce. Mod Gynek Porod 2002, 11, s. 565-571.

17. Melo, M., Busso, CE., Bellver, J., et al. GnRH agonist versus recombinant hCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online, 2009, 19, p. 486-492.

18. Sauer, MV., Paulson, RJ., Lobo, RA. A preliminary report on oocyte donation extending reproductive potential to women over 40. N Engl J Med, 1990, 323, p. 1157-1160.

19. Sismanoglu, A., Tekin, HI., Erden, HF., et al. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet, 2009, 26, p. 251-256.

20. Tarlatzis, BC., Fauser, BC., Kolibianakis, EM., et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update, 2006, 12, p. 333-340.